{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-086428","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.562527+00:00","generated_at":"2026-05-17T08:52:55.280444+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA issues Complete Response Letter to Outlook Therapeutics for ONS-5010 BLA; lacks efficacy evidence","bullets":["CRL cites lack of substantial evidence of effectiveness; ONS-5010 did not meet primary endpoint in NORSE EIGHT trial.","FDA recommends confirmatory evidence; NORSE TWO met primary endpoint but is not sufficient alone.","No other deficiencies in BLA; company plans to meet with FDA to discuss possible path to approval.","ONS-5010/LYTENAVA already approved in EU and UK; commercial launch in Germany and UK began June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-086428","json":"https://secwatch.observer/filing/0001104659-25-086428.json","markdown":"https://secwatch.observer/filing/0001104659-25-086428.md","text":"https://secwatch.observer/filing/0001104659-25-086428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/0001104659-25-086428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/tm2524956d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:52:55.280444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}